Abstract
This study reports the in vitro activities of vancomycin and teicoplanin against 185 coagulase-negative staphylococcal strains isolated from 80 neutropenic patients who received different antibiotic treatments. All strains were susceptible to vancomycin: MICs for 50 and 90% of strains tested were 2 and 4 mg/liter, respectively. Teicoplanin was less active, and MICs displayed a wider range. For only teicoplanin was there a correlation between resistance and previous treatment. At the 4- and 32-mg/liter breakpoint levels, only 20% of the strains isolated from patients without glycopeptide treatment were intermediate or resistant, whereas 49.2% of the strains from patients who had received vancomycin or teicoplanin or both were intermediate or resistant.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Arioli V., Pallanza R. Teicoplanin-resistant coagulase-negative staphylococci. Lancet. 1987 Jan 3;1(8523):39–39. doi: 10.1016/s0140-6736(87)90724-0. [DOI] [PubMed] [Google Scholar]
- Bauernfeind A., Petermüller C. In vitro activity of teichomycin A 2 in comparison with penicillin and vancomycin against gram-positive cocci. Eur J Clin Microbiol. 1982 Oct;1(5):278–281. doi: 10.1007/BF02019971. [DOI] [PubMed] [Google Scholar]
- Fainstein V., LeBlanc B., Bodey G. P. Comparative in vitro study of teichomycin A2. Antimicrob Agents Chemother. 1983 Mar;23(3):497–499. doi: 10.1128/aac.23.3.497. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Felmingham D., Solomonides K., O'Hare M. D., Wilson A. P., Grüneberg R. N. The effect of medium and inoculum on the activity of vancomycin and teicoplanin against coagulase-negative staphylococci. J Antimicrob Chemother. 1987 Oct;20(4):609–610. doi: 10.1093/jac/20.4.609. [DOI] [PubMed] [Google Scholar]
- Grant A. C., Lacey R. W., Brownjohn A. M., Turney J. H. Teicoplanin-resistant coagulase-negative staphylococcus. Lancet. 1986 Nov 15;2(8516):1166–1167. doi: 10.1016/s0140-6736(86)90580-5. [DOI] [PubMed] [Google Scholar]
- Harding I., Garaud J. J. Teicoplanin in the treatment of infections caused by coagulase-negative staphylococci. J Antimicrob Chemother. 1988 Jan;21 (Suppl A):93–103. doi: 10.1093/jac/21.suppl_a.93. [DOI] [PubMed] [Google Scholar]
- Jones R. N., Barry A. L. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob Agents Chemother. 1987 Apr;31(4):625–629. doi: 10.1128/aac.31.4.625. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mouton R. P., Mulders S. L. LY146032: activity and resistance development in vitro. J Antimicrob Chemother. 1987 Oct;20(4):513–517. doi: 10.1093/jac/20.4.513. [DOI] [PubMed] [Google Scholar]
- Pallanza R., Berti M., Goldstein B. P., Mapelli E., Randisi E., Scotti R., Arioli V. Teichomycin: in-vitro and in-vivo evaluation in comparison with other antibiotics. J Antimicrob Chemother. 1983 May;11(5):419–425. doi: 10.1093/jac/11.5.419. [DOI] [PubMed] [Google Scholar]
- Verbist L., Tjandramaga B., Hendrickx B., Van Hecken A., Van Melle P., Verbesselt R., Verhaegen J., De Schepper P. J. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother. 1984 Dec;26(6):881–886. doi: 10.1128/aac.26.6.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Watanakunakorn C. In-vitro induction of resistance in coagulase-negative staphylococci to vancomycin and teicoplanin. J Antimicrob Chemother. 1988 Sep;22(3):321–324. doi: 10.1093/jac/22.3.321. [DOI] [PubMed] [Google Scholar]
- Wilson A. P., O'Hare M. D., Felmingham D., Grüneberg R. N. Teicoplanin-resistant coagulase-negative staphylococcus. Lancet. 1986 Oct 25;2(8513):973–973. doi: 10.1016/s0140-6736(86)90622-7. [DOI] [PubMed] [Google Scholar]